title: Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors.
abstract: Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.
authors.affiliation: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France clement.morgat@chu-bordeaux.fr elif.hindie@chu-bordeaux.fr.
authors.forename: Clément
authors.initials: C
authors.lastname: Morgat
authors.affiliation: University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and.
authors.forename: Anil Kumar
authors.initials: AK
authors.lastname: Mishra
authors.affiliation: Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and.
authors.forename: Raunak
authors.initials: R
authors.lastname: Varshney
authors.affiliation: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France EPHE, Bordeaux, France.
authors.forename: Michèle
authors.initials: M
authors.lastname: Allard
authors.affiliation: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Fernandez
authors.affiliation: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France clement.morgat@chu-bordeaux.fr elif.hindie@chu-bordeaux.fr.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D010455:Peptides / Q000737:chemistry; D049268:Positron-Emission Tomography / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D018004:Receptors, Bombesin / Q000737:chemistry*; D017476:Receptors, Neuropeptide Y / Q000737:chemistry*; D018028:Receptors, Neurotensin / Q000737:chemistry*; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D010455:Peptides; D018004:Receptors, Bombesin; D017476:Receptors, Neuropeptide Y; D018028:Receptors, Neurotensin
keywords: PET; bombesin; cancer; molecular imaging; neuropeptide Y; neurotensin; peptide/neuropeptide; radiopharmaceutical; receptor